[{"arm_notes": "", "treatment_id": null, "treatment_name": "200 healthy volunteers will be recruited according to the inclusion and exclusion criteria as mentioned below. After taking informed consent they will be divided into four groups by computer-generated randomisation. Two groups will be given homologous vaccines and two groups will be given heterologous vaccines (mix and match). Blood samples will be collected 28 days after the 1st dose and 14 days after the 2nd dose. Participants will be closely monitored for any adverse effects for 3 months. Blood samples will be used for assessing S1; S2; and RBD specific antibody titres. Group 1 received Covishield on day 0 and Covishield on day 28 Group 2 received Covaxin on day 0 and Covaxin on day 28 Group 3 received Covishield on day 0 and Covaxin on day 28 Group 4 received Covaxin on day 0 and Covishield on day 28", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "2;Days0-28", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;Days0-28", "treatment_id": 1387, "treatment_name": "Covaxin", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1+1;Days 0 (Covishield) and 28 (Covaxin)", "treatment_id": 1898, "treatment_name": "Chadox1 ncov-19+covaxin", "treatment_type": "Non replicating viral vector+inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1+1;Days 0 (Covaxin) and 28 (Covishield)", "treatment_id": 1898, "treatment_name": "Chadox1 ncov-19+covaxin", "treatment_type": "Non replicating viral vector+inactivated virus", "pharmacological_treatment": "Vaccine"}]